GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
E

ENDRA Life Sciences NDRA · USD

Health Care · US listing · 🇺🇸 United States

Compare

4.84

+2.33%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About ENDRA Life Sciences

From its filings with the US Securities and Exchange Commission

SEC filings

ENDRA Life Sciences is based in Ann Arbor, Michigan and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker NDRA. The SEC classifies its business as electromedical & electrotherapeutic apparatus. In the fiscal year to 31 December 2020, it reported revenue of $0.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Health Care Equipment & Supplies
Listed since
28 Jun 2017
Employees
9
Head office
3600 GREEN COURT, ANN ARBOR, MI, 48105
Incorporated in
DE
Classification
Electromedical & Electrotherapeutic Apparatus
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Mr. Alexander TokmanChairman of the Board, Acting Chief Executive Officer, since 2008$215,185
  • Mr. Richard JacrouxChief Financial Officer, Principal Financial Officer and Principal Accounting Officer$95,900
  • Mr. Michael ThorntonChief Technology Officer$222,082
  • Mr. Louis BaseneseIndependent Director$40,954
  • Mr. Anthony DiGiandomenicoIndependent Director$40,954
  • Mr. Michael HarshIndependent Director$40,954
  • Ms. Yvonne BriggsInvestor Relations, since 2022

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Company develops medical imaging technology with Nexus 128 system combining light-based thermoacoustics and ultrasound.
  • The company has an IPO date of 2017-06-28.
  • The company employs 9 full-time employees as per the provided data.

Weaknesses

  • The company has a small employee count of 9, which may limit operational capacity.
  • The source description states 18 employees, conflicting with the provided 9 employees.
  • The company's technology is focused on pre-clinical applications, potentially limiting immediate market reach.

Opportunities

  • The TAEUS platform has potential clinical applications including distinguishing fat from lean tissue.
  • The technology enables real-time visualization of tissue temperature changes using ultrasound.
  • The firm's technology could expand ultrasound capabilities with new applications like capillary-level blood flow imaging.

Threats

  • The source description provides conflicting employee numbers, raising questions about data reliability.
  • The company's focus on pre-clinical research may delay commercialization and revenue generation.
  • The technology's reliance on new ultrasound systems could face adoption challenges from existing market players.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.